Sugi Predict

Sugi Predict / Compounds / SCHEMBL383066

SCHEMBL383066

SCHEMBL383066

CC(Nc1nc2ccccc2s1)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 8/20 0.59
▸ RAB9A P51151 8/20 0.59
▸ SMN1; SMN2 Q16637 8/20 0.59
▸ ALDH1A1 P00352 2/20 0.59
▸ ADORA1 P30542 1/20 0.59
▸ DYRK1A Q13627 1/20 0.59
▸ MEN1 O00255 3/20 0.56
▸ KMT2A Q03164 3/20 0.56
▸ GAA P10253 2/20 0.56
▸ CYP1A2 P05177 1/20 0.56
▸ CSNK1D P48730 3/20 0.56
▸ NFKB1 P19838 3/20 0.55
▸ NFKB2 Q00653 3/20 0.55
▸ RELA Q04206 3/20 0.55
▸ MAPT P10636 3/20 0.55
▸ NCS1 P62166 1/20 0.53
▸ POLB P06746 1/20 0.52
▸ CASP3 P42574 1/20 0.51
▸ SENP8 Q96LD8 1/20 0.51
▸ SENP7 Q9BQF6 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11105682 1.00 NPC1 (0.59) NPC1RAB9ASMN1; SMN2ALDH1A1ADORA1
SCHEMBL383067 1.00 NPC1 (0.59) NPC1RAB9ASMN1; SMN2ALDH1A1ADORA1
SCHEMBL22561728 0.87 NPC1 (0.58) NPC1RAB9ASMN1; SMN2ALDH1A1ADORA1
SCHEMBL11265639 0.84 PIK3CG (0.44) NPC1RAB9ASMN1; SMN2ALDH1A1ADORA1
SCHEMBL9963507 0.81 NPC1 (0.45) NPC1RAB9ASMN1; SMN2DYRK1AMEN1
SCHEMBL4458533 0.81 NPC1 (0.59) NPC1RAB9ASMN1; SMN2ALDH1A1ADORA1
SCHEMBL11106758 0.81 DYRK1A (0.62) NPC1RAB9ASMN1; SMN2ALDH1A1DYRK1A
SCHEMBL11989036 0.80 IDO1 (0.59) NPC1RAB9ASMN1; SMN2ALDH1A1ADORA1
SCHEMBL11100178 0.80 PPARA (0.57) SMN1; SMN2DYRK1ASENP7
SCHEMBL4456590 0.79 ADORA1 (0.52) NPC1RAB9ASMN1; SMN2ALDH1A1ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230310539-A1 TREATMENT OF DISEASE WITH EPOR ANTAGONIST EPO-MED INC. (JP) 2023-10-05 — — US claimed
EP-4190345-A1 TREATMENT OF DISEASE WITH EPOR ANTAGONIST Epo-Med Inc. (JP) 2023-06-07 — — EP claimed
CN-116234541-A Treatment of diseases by EpoR antagonists EPO医药株式会社 2023-06-06 — — CN claimed
WO-2022025204-A1 TREATMENT OF DISEASE WITH EPOR ANTAGONIST エポメッド株式会社 2022-02-03 — — WO claimed
CN-113166203-A Anti-erythropoietin receptor peptides EPO医药株式会社 2021-07-23 — — CN claimed
EP-3851448-A1 ANTI-ERYTHROPOIETIN RECEPTOR PEPTIDE EPO-Med Inc. (JP) 2021-07-21 — — EP claimed
WO-2020054813-A1 ANTI-ERYTHROPOIETIN RECEPTOR PEPTIDE エポメッド株式会社 2020-03-19 — — WO claimed
US-20180355025-A1 MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS SEATTLE GENETICS INC. 2018-12-13 — — US claimed
EP-2722051-A1 Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus Seattle Genetics, Inc. (US) 2014-04-23 — — EP claimed
US-20090018086-A1 Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus SEATTLE GENETICS, INC. (US) 2009-01-15 — — US claimed
EP-1917020-A1 MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS Seattle Genetics, Inc. (US) 2008-05-07 — — EP claimed
EP-1761554-A2 PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME Biosource Pharm, Inc. (US) 2007-03-14 — — EP claimed
WO-2007008603-A1 MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS SEATTLE GENETICS, INC. (US) 2007-01-18 — — WO claimed
WO-2006083317-A2 PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME BIOSOURCE PHARM, INC. (US) 2006-08-10 — — WO claimed
WO-1997046553-A1 THROMBIN INHIBITORS NOVARTIS AG (CH) 1997-12-11 — — WO claimed
US-20250263685-A1 OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF GENZYME CORPORATION 2025-08-21 — — US disclosed
US-12024571-B2 Anti-erythropoietin receptor peptide EPO-MED INC. (JP) 2024-07-02 — — US disclosed
WO-2007008603-A1 MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS SEATTLE GENETICS, INC. (US) 2007-01-18 — — WO disclosed
WO-2006083317-A2 PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME BIOSOURCE PHARM, INC. (US) 2006-08-10 — — WO disclosed
WO-1997046553-A1 THROMBIN INHIBITORS NOVARTIS AG (CH) 1997-12-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12024571-B2 Anti-erythropoietin receptor peptide EPOR, PRLHR, AVPR1A NPC1 4648/4885RAB9A 2945/4885SMN1; SMN2 4254/4885
US-20230310539-A1 TREATMENT OF DISEASE WITH EPOR ANTAGONIST EPOR, PROKR1, HBZ NPC1 4106/4885RAB9A 1754/4885SMN1; SMN2 378/4885
US-20180355025-A1 MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS MMAB, PTMS, DNPEP NPC1 1942/4885RAB9A 2337/4885SMN1; SMN2 4294/4885
US-20090018086-A1 Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus MMAB, DNPEP, MARCKS NPC1 1970/4885RAB9A 2318/4885SMN1; SMN2 4221/4885
US-20250263685-A1 OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF MAN2B1, MAN1B1, GAA NPC1 251/4885RAB9A 757/4885SMN1; SMN2 1269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.